Table 1.
Characteristics of 155 MPP Children with A2063/2064G Mutation
| Characteristics | Total (n=155) |
|---|---|
| Demographic data | |
| Age (years) (median, IQR) | 6.17 (4.21–8.04) |
| Male (n, %) | 77 (49.68%) |
| Underlying condition | |
| Viral coinfection (n, %) | 35 (22.58%) |
| Bacterial coinfection (n, %) | 18 (11.61%) |
| Laboratory data | |
| WBC (10^9/L) (median, IQR) | 6.81 (5.25–9.33) |
| CRP (mg/L) (median, IQR) | 22.22 (11.93–37.00) |
| PCT (ng/mL) (median, IQR) | 0.21 (0.10–0.53) |
| Fibrinogen (g/L) (median, IQR) | 4.52 (3.87–4.90) |
| D-dimer (ng/mL) (median, IQR) | 1.00 (0.47–2.17) |
| Albumin (g/L) (median, IQR) | 40.20 (35.60–43.30) |
| ALT (U/L) (median, IQR) | 18.00 (13.00–25.00) |
| AST (U/L) (median, IQR) | 36.00 (29.00–46.00) |
| LDH (U/L) (median, IQR) | 337.00 (283.00–465.65) |
| Chest imaging data | |
| Lung consolidation (n, %) | 123 (79.35%) |
| Pleural effusion (n, %) | 49 (31.61%) |
| With cephalosporins or penicillin | 77 (49.68%) |
| Requiring for CPAP (n, %) | 23 (14.84%) |
| Therapy adjustment during hospitalization | |
| Application of glucocorticoid (n, %) | 47 (30.32%) |
| Application of quinolones (n, %) | 44 (28.39%) |
| Application of immunoglobulin (n, %) | 28 (18.06%) |
| Fever duration before azithromycin therapy (days) (median, IQR) | 5.00 (4.00–7.00) |
| Total fever duration (days) (median, IQR) | 10.00 (9.00–13.00) |
| Cough duration before azithromycin therapy (days) (median, IQR) | 4.00 (3.00–6.50) |
| Total cough duration (days) (median, IQR) | 16.00 (13.50–19.00) |
| Length of stay (days) (median, IQR) | 14.00 (11.32–17.59) |
| MUMPP (n, %) | 119 (76.77%) |
| RMPP (n, %) | 54 (34.84%) |
| Poor prognosis within one year after discharge | 16 (10.32%) |
| Bronchiolitis obliterans (n, %) | 11 (7.10%) |
| Bronchiectasis (n, %) | 5 (3.23%) |
Abbreviations: CPAP, Continuous positive airway pressure; MPP, Mycoplasma pneumoniae pneumonia; MUMPP, Macrolides-unresponsive Mycoplasma pneumoniae pneumonia; RMPP, Refractory Mycoplasma pneumoniae pneumonia.